Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2<i>H</i>)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
Pei‐Pei Kung(Pfizer (United States)), Martin A. Edwards(University of Utah), Luke R. Zehnder(University of Minnesota), Sacha Ninkovic(Pfizer (United States)), Michael Ryskin(Pfizer (United States)), John Braganza(Pfizer (United States)), Mei Cui(Huashan Hospital), Patrick Bingham(Pfizer (United States)), Simon Bergqvist(Pfizer (United States)), Shinji Yamazaki, Susan E. Kephart(Pfizer (United States)), Robert A. Kumpf(Pfizer (United States)), Valeria R. Fantin(AVEO Oncology (United States)), Peter Wells(Cardiff University), Martin Wythes(Pfizer (United States)), Indrawan McAlpine(Pfizer (United States)), Hovhannes J. Gukasyan(Pfizer (United States)), Karen A. Maegley(Pfizer (United States)), Wenyue Hu(Beijing University of Chinese Medicine), Martha Ornelas, Eugene Rui(Unknown), Michael J. Collins(Queensland University of Technology), Dominique Verhelle(Pfizer (United States)), S. Scott Sutton, Brian Yip(Pfizer (United States)), Wade Diehl(Pfizer (United States)), Cody Krivacic(Pfizer (United States)), Weiguo Zhang(Northwestern Polytechnical University), Gang Li(Pfizer (United States)), Fen Wang, Yu Xiu(Southern University of Science and Technology), Dac M. Dinh(Pfizer (United States)), Stephanie Scales(Pfizer (United States)), John Tatlock(Pfizer (United States)), Robert A. Rollins(Pfizer (United States)), Connie Fan(Pfizer (United States)), Buwen Huang(Pfizer (United States)), Lisa Nguyen(Pfizer (United States))
Cited by 4
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance
|Cancer Cell|2006|1.6k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924